Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Houston Methodist Hospital has 7 pending office actions in Biotechnology & Pharmaceuticals. The portfolio involves 7 distinct examiners and 7 distinct art units, indicating complete separation across the recorded examination assignments.
ALLEY, GENEVIEVE S is the busiest examiner, with 1 pending matter. A coordinated docketing process should preserve separate response strategies for each matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 2 (29%) |
| §102 only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEY, GENEVIEVE S | 1 | 60.5% | +48.3% |
| SHELDEN, BION A | 1 | 22.1% | +20.1% |
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| BELYAVSKYI, MICHAIL A | 1 | 63.9% | +28.0% |
| NICKOL, GARY B | 1 | 46.6% | +33.3% |
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
| TAKENAKA, RISA | 1 | 26.1% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18875400 | DEVICES AND METHODS OF MAKING AND USE THEREOF | ALLEY, GENEVIEVE S | — |
| 18794147 | SYSTEM AND METHOD FOR AUTOMATICALLY AND CONTINUOUSLY MONITORING MEDICATION DELIVERY TO A PATIENT | SHELDEN, BION A | — |
| 18683238 | METHODS AND COMPOSITIONS FOR VACCINATION AGAINST HETEROSUBTYPIC INFLUENZA VIRUSES USING AN ADENOVIRAL VECTOR LEADING TO ENHANCED T CELL RESPONSE THROUGH AUTOPHAGY | CHESTNUT, BARRY A | — |
| 16964548 | METHODS OF FORMING CARDIOMYOCYES | TAKENAKA, RISA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18875400 | DEVICES AND METHODS OF MAKING AND USE THEREOF | ALLEY, GENEVIEVE S | — |
| 18794147 | SYSTEM AND METHOD FOR AUTOMATICALLY AND CONTINUOUSLY MONITORING MEDICATION DELIVERY TO A PATIENT | SHELDEN, BION A | — |
| 18278736 | Regulatory T Cell (Treg) Extracellular Vesicle Compositions and Methods | BELYAVSKYI, MICHAIL A | — |
| 18212127 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND CHIMERIC ANTIGEN RECEPTORS, AND METHODS OF USE IN IMMUNE SIGNALING MODULATION FOR CANCER IMMUNOTHERAPY | NICKOL, GARY B | — |
| 17292423 | REGULATORY T CELL (TREG) COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | KIM, YUNSOO | — |
| 16964548 | METHODS OF FORMING CARDIOMYOCYES | TAKENAKA, RISA | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 3685 | 1 |
| 1672 | 1 |
| 1644 | 1 |
| 1643 | 1 |
| 1641 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18875400 | DEVICES AND METHODS OF MAKING AND USE THEREOF | ALLEY, GENEVIEVE S | 1617 | §102§112 | Non-Final OA | — | Pending | Dec 16, 2024 |
| 18794147 | SYSTEM AND METHOD FOR AUTOMATICALLY AND CONTINUOUSLY MONITORING MEDICATION DELIVERY TO A PATIENT | SHELDEN, BION A | 3685 | §101§103§112 | Final Rejection | — | Pending | Aug 05, 2024 |
| 18683238 | METHODS AND COMPOSITIONS FOR VACCINATION AGAINST HETEROSUBTYPIC INFLUENZA VIRUSES USING AN ADENOVIRAL VECTOR LEADING TO ENHANCED T CELL RESPONSE THROUGH AUTOPHAGY | CHESTNUT, BARRY A | 1672 | §102§103§112 | Non-Final OA | — | Pending | Feb 12, 2024 |
| 18278736 | Regulatory T Cell (Treg) Extracellular Vesicle Compositions and Methods | BELYAVSKYI, MICHAIL A | 1644 | §102 | Non-Final OA | — | Pending | Aug 24, 2023 |
| 18212127 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND CHIMERIC ANTIGEN RECEPTORS, AND METHODS OF USE IN IMMUNE SIGNALING MODULATION FOR CANCER IMMUNOTHERAPY | NICKOL, GARY B | 1643 | §102§112DP | Non-Final OA | — | Pending | Jun 20, 2023 |
| 17292423 | REGULATORY T CELL (TREG) COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | KIM, YUNSOO | 1641 | §103 | Non-Final OA | — | Pending | May 07, 2021 |
| 16964548 | METHODS OF FORMING CARDIOMYOCYES | TAKENAKA, RISA | 1600 | §103 | Final Rejection | — | Pending | Jul 23, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHouston Methodist Hospital has 7 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
Genevieve S Alley has the most, with 1 of Houston Methodist Hospital's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
